

THE ARTEMISININ ENTERPRISE CONFERENCE

Exploring new sources of artemisinin



THE 2008 ARTEMISININ ENTERPRISE CONFERENCE
October 8-10 York UK

**Meeting the Malaria Treatment Challenge:
Effective introduction of new technologies for a sustainable supply of ACTs**

Focus

The focus of the Artemisinin Enterprise (AE) Conference, which is co-sponsored by the Roll Back Malaria Partnership, will be the role of the AE and the new technologies that the three partners are developing for introduction into the Artemisinin Combination Therapy (ACT) supply chain. Delegates to the meeting will include stakeholders from the entire supply chain, from growers to producers of active pharmaceutical ingredients (APIs) and ACT manufacturers and will also include representatives from malaria-endemic countries, international technical organizations, and other relevant contributors.

The objectives of the conference will be to:

- Inform stakeholders in the supply chain about the technology projects undertaken by the AE
- Assess the potential impacts of the new technologies – opportunities and challenges
- Explore the timelines for introduction of the new AE technologies, strategies for their effective introduction and integration into the supply chain
- Define how the AE can interface with the efforts of the Roll Back Malaria Procurement and Supply Chain Management (RBM-PSM) and Affordable Medicines Facility for malaria (AMFm) working groups, and the Medicines for Malaria Venture (MMV) Access group

Structure of the meeting

The meeting, to be held over a period of two and a half days, will include presentations, panel discussions and a breakout session. Stakeholders representing all the relevant sectors will participate in the breakout groups. The major output from the conference will come from these groups. They will:

- Provide new understanding of the impact of the new technologies; discuss potential challenges that may result from their introduction
- Propose strategies to overcome these problems and suggest actions needed to ensure effective progress

The discussions and recommendations of the AE Conference will be assimilated into a final report that will be shared with the attendees and global stakeholder community (including RBM-PSM, AMFm Task Force and MMV Access group).

For those individuals who are not able to attend in person, arrangements will be made to broadcast the conference over the internet.

There will be an opportunity to visit the facilities of the Centre for Novel Agricultural Products (CNAP) at the University of York and meet the CNAP Artemisia Research Project team.


CNAP
CENTRE FOR NOVEL AGRICULTURAL PRODUCTS
BIOLOGY TO BENEFIT SOCIETY

Department of Biology

THE UNIVERSITY of York



Medicines for Malaria Venture



Day 1 October 8

1200-2000

Registration of participants

Session 1: Opening and keynote lecture

1400-1630	Introduction to the Centre for Novel Agricultural Products (CNAP) at the University of York, tour of laboratory facilities and CNAP Artemisia Research Project (optional)	Professor Dianna Bowles, Chair of Biochemistry, CNAP, University of York
1800-2000	Reception in the Atrium of the Department of Biology with buffet dinner and drinks	Welcome by Professor Brian Cantor, Vice-Chancellor, University of York
2000-2100	Keynote lecture	Mr Alan Court, Senior Adviser to the Office of the Secretary General's Special Envoy for Malaria, United Nations

Day 2 October 9


0800-0845

Continued registration of participants

Session 2: New technologies for artemisinin supply from the Artemisinin Enterprise

Chair for the session: Stephen O'Brien MP
Chairman of the UK All Party Parliamentary Group on Malaria

0845-0900	Introductory remarks	Mr Alan Court, Senior Adviser to the Office of the Secretary General's Special Envoy for Malaria, United Nations
0900-0915	Overview of the Artemisinin Enterprise	Dr Tom Brewer, Senior Program Officer, Bill and Melinda Gates Foundation
0915-1000	Fast-track breeding of high-yielding varieties of <i>Artemisia annua</i>	Professor Ian Graham, Weston Chair of Biochemical Genetics, Director, CNAP, University of York
1000-1045	Semi-synthetic artemisinin: a new source of artemisinin from synthetic biology	Dr Tue Nguyen, Vice President, Institute for One World Health
1045-1115	Coffee	
1115-1200	Novel synthetic therapies for the treatment of malaria	Dr Ian Bathurst, Director of Drug Discovery and Technology, Medicines for Malaria Venture



Session 3: Current context for ACTs


Chair for the session: Stephen O'Brien MP
Chairman of the UK All Party Parliamentary Group on Malaria

1200-1230	Background structure and challenges of the current ACT supply chain - gaps and issues	Professor Christopher Whitty, Chair of International Health, London School of Hygiene and Tropical Medicine
1230-1330	Lunch	

Session 4: Context for introducing the new AE technologies into the ACT supply chain

Chair for the session: Silvio Gabriel
Executive Vice President, Head of Malaria Initiatives, Novartis

1330-1335	Introductory remarks	Chair
1335-1425	Panel updates on current challenges in API sourcing strategies	Dr Björn Treptow, Novartis Dr Valerie Faillat-Proux, Sanofi Aventis Dr Antonio Longo, Sigma Tau Dr Won June Chang, Shin Poong Dr D C Jain, IPCA
1425-1455	Panel updates on regulation and prequalification of artemisinin APIs	Dr Raul Kiivet, WHO Prequalification of Medicines Programme Dr Hashim Yusufu, National Agency for Food, Drug Administration and Control, Nigeria
1455-1525	Tea	
1525-1535	Role of a donor in malaria control	Dr Dana Dalrymple, Senior Research Adviser, USAID
1535-1555	Financing – the changing landscape with AMFm	Dr Jan Van Erps, Commodity Services Coordinator, Roll Back Malaria Partnership
1555-1610	CHAI demand forecasting	Dr Inder Singh, Director of Drug Access, CHAI/Clinton Foundation
1610-1625	Demand forecasting – current and future issues	Professor Prashant Yadav, Chair of Logistics Systems, MIT Zaragoza
1625-1715	Panel discussions: Manufacturers' reflection on the session 4 updates and issues raised	Dr Björn Treptow, Novartis Dr Valerie Faillat-Proux, Sanofi Aventis Dr Antonio Longo, Sigma Tau Dr Won June Chang, Shin Poong Dr D C Jain, IPCA
1715-1725	Closing remarks	Chair
1900 -2200	Reception and dinner at Merchant Adventurers' Hall Dinner speech: Sustainability in agricultural supply chains in the developing world	Dr Harry Swaine, Syngenta AG



Day 3 October 10

Session 5: Breakout session: Introducing new AE technologies – impacts and issues

Chair for the session: Chris Hentschel
President and Chief Executive Officer, Medicines for Malaria Venture

0845-0915	Introduction to the rationale for the breakout session and guidelines for discussion	Ian Boulton, TropMed Pharma Consulting
0930-1245	Breakout session with facilitators	<p>The session will address:</p> <ul style="list-style-type: none"> - Potential impact of the new technologies and how they could change the current situation - Potential challenges in the introduction of new technologies - The strategies to be adopted to maximise the effectiveness of introducing the new technologies - Actions to be prioritised and undertaken now to overcome potential challenges arising at the time of introduction of the new technologies
1300-1400	Lunch	
1400-1545	Presentation of reports from breakout groups, followed by plenary discussion	
1545-1615	Tea	

Session 6: Future actions

Chair for the session: Tom Brewer
Senior Program Officer, Bill and Melinda Gates Foundation

1615-1645	Review of reports and summing up of breakout session	Ian Boulton, TropMed Pharma Consulting
1645-1800	Panel discussion of breakout conclusions, how best to start working to introduce AE new technologies into the API/ACT supply chains and develop a set of agreed future actions	<p>Professor Awa Coll-Seck, Executive Director, Roll Back Malaria Partnership Dr Chris Hentschel, Medicines for Malaria Venture Dr Tom Brewer, Bill and Melinda Gates Foundation Professor Jean-Paul Moatti, Global Fund Dr Jan Van Erps, Roll Back Malaria Partnership</p>
1800-1815	Concluding remarks	Professor Awa Coll-Seck, Executive Director, Roll Back Malaria Partnership
1815-1830	Final comments	Professor Dianna Bowles on behalf of the Artemisinin Enterprise
1830 onwards	Closing reception and buffet dinner in the Atrium of the Department of Biology	